NEO212

Developed for: cervical cancer · colorectal cancer · cutaneous neuroendocrine carcinoma · diffuse astrocytoma · esophageal squamous cell carcinoma · gastric cancer · gastroesophageal junction adenocarcinoma · head and neck squamous cell carcinoma
+7 more
· IDH-wildtype glioblastoma · melanoma · metastatic malignant neoplasm in the brain · non-small cell lung carcinoma · renal cell carcinoma · small cell lung carcinoma · urothelial carcinoma
Investigated by: Neonc Technologies, Inc.

today NCT06047379 · Ph 1/2

2024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT06047379	Nov 2023 → Feb 2027 expected	IDH-wildtype glioblastoma, cervical cancer, colorectal cancer, cutaneous neuroendocrine carcinoma +11	Neonc Technologies, Inc.	Recruiting	No outcome recorded

Date	Issuer	Release
2026-06-16	Neonc Technologies, Inc.	Regulatory NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development neonc.com ↗ NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO212, the Company’s orally administered perillyl alcohol-temozolomide carbamate conjugate being developed for patients with aggressive brain tumors.
2026-03-04	Neonc Technologies, Inc.	Results NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management Hosted KOL Conference Call neonc.com ↗ NeOnc has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort 5 (810 mg, Days 1–5, 28-day cycle) following a second Dose-Limiting Toxicity.
2025-09-10	Neonc Technologies, Inc.	Regulatory NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 neonc.com ↗

Date	Issuer	Release
2026-09-28	Neonc Technologies, Inc.	NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212 neonc.com ↗
2026-07-15	Neonc Technologies, Inc.	NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition neonc.com ↗
2026-06-16	Neonc Technologies, Inc.	NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development neonc.com ↗
2026-03-04	Neonc Technologies, Inc.	NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management Hosted KOL Conference Call neonc.com ↗
2026-02-27	Neonc Technologies, Inc.	NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity neonc.com ↗
2025-09-10	Neonc Technologies, Inc.	NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 neonc.com ↗
2025-04-08	Neonc Technologies, Inc.	NeOnc Nears Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy neonc.com ↗
2024-07-24	Neonc Technologies, Inc.	NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212 neonc.com ↗

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	NEO212	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06047379 ↗